BioWorld MedTech

March 20, 2013

Chinese med-tech firm seeks to win in China, then disrupt U.S. market

SHANGHAI – In China, local med-tech manufacturers have successfully pushed multinationals' products to the side at least in some product lines, due to strong government incentives, their low cost and improved quality. Read More

To go or not to go: study examines obesity and THA

Washington roundup: House hearing calls on FDA to finalize mobile guidance

DiaTech assay helps docs tailor cancer treatment

Deals roundup: DSM and SpineVision in license, supply agreement for Bionate II

Financings roundup: HPT prices public offering of 14M shares at $25.55

Report from Europe: InspireMD wins CE mark for Nitinol carotid EPS

Agreements/contracts: GSD establishes distribution partnerships for Thunderbolt

Product Briefs

People in the News

Keeping you up to date on recent developments in oncology

Today's news in brief

BioWorld

BioWorld briefs for Nov. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 27, 2024.

Illustration of man holding magnifying glass to human body model showing muscle anatomy

In muscular dystrophies, gene therapies race the clock

BioWorld

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...

AI-generated illustration of heart and metabolic impact

Bridgebio, with FDA approval, faces Pfizer in ATTR

BioWorld

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...

‘Evo’ AI can design complete genomes

BioWorld Science

The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...